1-[2-(4-氯苯基)乙基]-1,2,3,4-四氢-6-甲氧基-2-甲基-7-异喹啉醇盐酸盐 | 64047-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 1-[2-(4-氯苯基)乙基]-1,2,3,4-四氢-6-甲氧基-2-甲基-7-异喹啉醇盐酸盐
• 英文名称: Ro 04-5595 hydrochloride
• 英文别名: 1-[2-(4-chlorophenyl)ethyl]-6-methoxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-ol;hydrochloride
• CAS: 64047-73-0
• 化学式: C19H23Cl2NO2
• 分子量: 368.3
• InChiKey: NVIPBLQAFKRFSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  33.9
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA<br/>[FR] DÉRIVÉS D'ACIDE GLYCYRRHÉTINIQUE DE TRAITEMENT DE L'HYPERKALIÉMIE
  申请人：ARDELYX INC

  公开号：WO2019060051A1

  公开（公告）日：2019-03-28

  The present invention provides a compound of formula (I) or a salt thereof: (I) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. These compounds are inhibitors of 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and are used to treat hyperkalemia.

  本发明提供了化合物(I)或其盐：(I)其中X、L、V、R1、R2、R3和R4如本文所定义。这些化合物是11-羟基类固醇脱氢酶2型（11-HSD-2）的抑制剂，用于治疗高钾血症。
• Methods and compositions for the treatment of alzheimer
  申请人：Universidad del Pais Vasco

  公开号：EP2338492A1

  公开（公告）日：2011-06-29

  The invention relates to AMPA receptor inhibitors and NMDA receptor inhibitors for use in the treatment of a disease associated with deposition of amyloid proteins, more precisely, Alzheimer.

  本发明涉及 AMPA 受体抑制剂和 NMDA 受体抑制剂，用于治疗与淀粉样蛋白沉积有关的疾病，更确切地说，是阿尔茨海默病。
• A DRUG SCREENING PLATFORM FOR RETT SYNDROME
  申请人：The Regents of the University of California

  公开号：EP2841067A2

  公开（公告）日：2015-03-04
• GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA
  申请人：Ardelyx, Inc.

  公开号：EP3661945A1

  公开（公告）日：2020-06-10
• DRUG SCREENING PLATFORM FOR RETT SYNDROME
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150119327A1

  公开（公告）日：2015-04-30

  The invention provides a method for restoring a neural cell having a deficiency or alteration in glutamatergic pathway affecting neuron and/or glial function comprising contacting the cell with a NMDA receptor antagonist(s) and/or modulator(s) of a glutamatergic pathway, thereby restoring the neural cell having a deficiency or alteration in glutamatergic pathways affecting neuron and/or glial function.